ID: ALA247261

Max Phase: Preclinical

Molecular Formula: C20H30BrNO5

Molecular Weight: 444.37

Molecule Type: Small molecule

Representations

Canonical SMILES:  COC(=O)[C@H](CC(=O)O)NC(=O)/C=C/C(C)(C)C/C=C(\C)CC/C=C(\C)Br

Standard InChI:  InChI=1S/C20H30BrNO5/c1-14(7-6-8-15(2)21)9-11-20(3,4)12-10-17(23)22-16(13-18(24)25)19(26)27-5/h8-10,12,16H,6-7,11,13H2,1-5H3,(H,22,23)(H,24,25)/b12-10+,14-9+,15-8+/t16-/m0/s1

Standard InChI Key:  FUWFOPNLWHUEOU-OEMRDNBMSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 444.37

Molecular Weight (Monoisotopic): 443.1307

AlogP: 4.12

#Rotatable Bonds: 11

Polar Surface Area: 92.70

Molecular Species: ACID

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 4.31

CX Basic pKa:

CX LogP: 3.72

CX LogD: 0.76

Aromatic Rings: 0

Heavy Atoms: 27

QED Weighted: 0.28

Np Likeness Score: 0.95

References

1. Kitayama T, Iwabuchi R, Minagawa S, Sawada S, Okumura R, Hoshino K, Cappiello J, Utsumi R..  (2007)  Synthesis of a novel inhibitor against MRSA and VRE: preparation from zerumbone ring opening material showing histidine-kinase inhibition.,  17  (4): [PMID:17157007] [10.1016/j.bmcl.2006.11.015]

Source

Source(1):

• Scientific Literature